1. 25 - 26
MAR
2015Holiday Inn Regents Park Hotel, London, UK
Superbugs &
Superdrugs
@SMIPHARM
www.superbugssuperdrugs.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
CHAIR FOR 2015:
• Richard Bax, Senior Partner, TranScrip
Partners
KEY SPEAKERS INCLUDE:
• Jorge Mestre-Ferrandiz, Director of
Consulting, Office of Health Economics (OHE)
• Shiva Dustdar, Head of Research,
Development and Innovation Advisory,
European Investment Bank (EIB)
• Fiona Marston, Chief Executive, Absynth
Biologics
• Colin J Suckling, Research Professor of
Chemistry, University of Strathclyde
• David Findlay, Commercial Director of II-ID
Global Franchise, GSK
• William Weiss, Director of Pre-Clinical Services,
University of North Texas Health Science
Center
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 24th March, Holiday Inn Regents Park Hotel, London
A: A Vision for the Future; Designing
Antimicrobials to Meet Future Needs
Workshop Leader: Dr Keith Williams, Director and Consultant,
KW Drug Developments Ltd & Boyd Consultants
8.30am – 12.30pm
B: Technical Aspects of Licensing an Antibiotic
Workshop Leader:
David Scott, Consultant, PharmaConsulting
1.30pm – 4.30pm
BUSINESS BENEFITS FOR 2015:
• Receive the latest updates and case studies on
preclinical and clinical developments
• Scan horizons on anti-microbial resistance and
understand initiatives to control antimicrobial use
• Look at alternative approaches including phage
and minor groove binders
• Explore the latest updates in funding and
reimbursement
• Review the current status of antimicrobial
resistance and the threats and targets landscape
• Discuss the potential of rapid point of care
diagnostics
BO
O
K
BY
28TH
N
O
VEM
BER
SAVE
£300
BO
O
K
BY
30TH
JA
N
UA
RY
SAVE
£100
SMi presents the 17th annual conference on…
The Latest in Antibacterial Therapies, Funding and Partnerships
“Very well organised conference” – GSK
“Very good and engaging speakers” – Merck

2. Register online at: www.superbugssuperdrugs.com • Alternatively fa
Superbugs and Superdrugs
Day One | Wednesday 25th March 2015
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Richard Bax, Senior Partner, TranScrip Partners
PARTNERSHIPS AND PRICING - PART ONE
9.10 Time for the big deal - mission impossible?
• Explore models of effective industry incentives
• How can new antibiotics be made available
at affordable prices around the world?
• Strategies for usage control to avoid development of
resistance
Richard Bergstrom, Director General, EFPIA
9.50 Do we need new business models for rewarding new antibiotics?
• Economic challenges - is there a need for a new business
model?
• Incentives - what has worked in the past?
• Addressing the challenges - what could be the new business
model?
• On-going initiatives
Jorge Mestre-Ferrandiz, Director of Consulting, Office of Health
Economics (OHE)
10.30 Morning Coffee
11.00 The changing role of academia in antimicrobial drug discovery
• Historical perspective of academic involvement in drug
development
• Growth of the modern pharmaceutical industry and
detachment from academia
• Downturn in antibacterial discovery and development and
current need for increased research capabilities
• Collaboration of industry and academia in drug discovery and
development
• Novel partnering models to increase innovation in
pharmaceutical R&D
William Weiss, Director of Pre-Clinical Services, University of North
Texas Health Science Center
11.40 SETTING THE AGENDA
Partnering and working with BARDA
• Discuss recent US government initiatives for
countering antimicrobial resistance
• Discuss how those initiatives impact BARDA’s future
investments
• Understand BARDA’s research priorities and areas of interest
• Learn how BARDA forms partnerships for the development of
antibacterial therapies
Melissa Stundick, Acting Branch Chief, Broad Spectrum
Antimicrobials Program, BARDA
12.20 Networking Lunch
RESEARCH AND DEVELOPMENT UPDATES - PART ONE
1.20 Thousands of new antibiotic classes: The road to patients
• New small molecule discovery paradigm
• The use of new technologies
• A novel validated approach to anti-bacterial therapy
David Williams, Chief Executive Officer, Discuva
2.00 Where have all the bugs gone? Challenges in enrolling resistant
pathogen studies
• Resistant Gram negative infections are a worldwide threat
however, challenges to conducting acceptable studies
focused on resistant pathogens are numerous
• Development pathways relying on such studies require flexibility
• Potential ways forward are suggested
Ian Friedland, Chief Medical Officer, Achaogen, Inc.
2.40 PhagoBurn: from cold war to “hot” phage therapy
• The band: Pherecydes Pharma and the French Defence
Health Service
• The tune: Phage against MDR E. coli and P. aeruginosa bacteria
• The gear: PhagoBurn, 1st phage therapy multicentre
European trial
Jérôme Gabard, CEO, Pherecydes
3.20 There's no escape - single target, multiple effects
• A dirty drug to clean up infection?
• Catastrophic failure in a bug
• Chemical mechanism, biological consequence
• Is it safe to target DNA?
Colin J Suckling, Research Professor of Chemistry, University of
Strathclyde
4.00 Afternoon Tea
4.30 Superdrugs against multiresistant bacterial strains and
superinfection: Super disaster for Big Pharma?
• The uncontrolled use of antibiotics in animal husbandry
provokes the increase in bacterial resistance, such as seen for
MRSA and ESBL
• Primary infection may lead to a superinfection with Herpes or
Influenza viruses
• New 'Superdrugs' are able to block this infection, as shown in a
case study patient presenting with a mucosal mouth infection
Klaus Brandenburg, Chief Scientific Officer, Brandenburg
Antiinfektiva
5.10 Prevention is better than cure?
• Is there a role for vaccines in the fight against microbial drug
resistance?
• Why is it proving difficult to develop a Staph. aureus vaccine?
• A different approach – to improve chances of success
• A platform for other vaccines
Fiona Marston, Chief Executive, Absynth Biologics
5.50 Discussion Panel: How to de-risk and optimise clinical
development of antimicrobials
Richard Bax, Senior Partner, TranScrip Partners
6.20 Chairman's Closing Remarks and Close of Day One
Richard Bax, Senior Partner, TranScrip Partners
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages,
uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand
your client base within the context of an independent discussion specific
to your industry.
Should you wish to join the increasing number of companies benefiting
from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email:
amalick@smi-online.co.uk
KEYNOTE
ADDRESS
KEYNOTE
ADDRESS
Official Media Partners

3. ax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Superbugs and Superdrugs
Day Two | Thursday 26th March 2015
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Richard Bax, Senior Partner, TranScrip Partners
RESEARCH AND DEVELOPMENT UPDATES - PART TWO
9.10 50 years of frustration. What have we learned? What can we
do to escape from this nightmare?
• Despite the enormous efforts in industry research for
discovering broad-spectrum antibacterials with new
mechanisms of action, the newest molecular mechanism
of action is 50 years old. What can we do to provide
solutions to this dangerous fact?
• Attrition is a major issue in drug discovery and
development, making the drug development process
enormously inefficient and costly. Can we be more
successful?
• The business opportunities in infectious diseases, necessarily
go through a radical paradigm shift and high doses of
disruptive innovation.
• To improve productivity and delivery, it is necessary to
review topics such as: target product profile, drug
discovery strategy and collaborations
Domingo Gargallo-Viola, Chief Scientific Officer, ABAC Therapeutics
9.50 Novel inhibitors of topoisomerases for drug-resistant
bacteria
• Strategies for new antibacterial discovery
• Gram-positive inhibitors with potent activity against MRSA
• Broad-spectrum agents for MDR Gram-negatives
• Innovative partnerships in antibiotic development
Neil Stokes, Head of Biology, Redx Anti-Infectives
10.30 Morning Coffee
11.00 Search for new antibacterials using diversity-oriented synthesis
• The discovery of antibacterials with a novel mode of action
is needed
• Current small molecule screening collections are not
structurally diverse
• The efficient synthesis of structural diversity followed by
antibacterial phenotypic screening can be a successful
approach
• Target identification from phenotypic hit compounds is still
a challenge
David Spring, Professor of Chemistry, Cambridge University
11.40 Debio1450: Another drug against Staphylococci?
• Description of the mechanism of action of a new antibiotic
with narrow specificity
• To understand the impact of antibiotics on the human
microbiome
• Understand the current status of development of Debio1450
Frederick Wittke, Medical Director, Debiopharm International
12.20 Networking Lunch
1.20 Proof of concept investigation of intravenous MGB-BP-3, a
new class of anti-bacterial
• New class of anti-infectives for the treatment of C. difficile
infections
• Efficacy: MGB-BP-3 v’s gold standard
• Benefits to NHS and patients
• Use in line with antibiotic stewardship to combat resistance
Dawn Firmin, Head of Project Management, MGB Biopharma
2.00 Anti-gram-negative drug discovery: A humbling test of
perseverance
• What to target (and how that reveals the limitations of our
scientific creativity)
• Why is it so difficult to find the right chemistry and achieve
potency?
• Key challenges in translation
Ryan Cirz, Director of Biology, Achaogen, Inc.
2.40 Round Table: How to best ensure a reliable
pipeline of appropriate drugs?
Richard Bax, Senior Partner, TranScrip Partners
PARTNERSHIPS AND PRICING - PART TWO
3.20 DRIVE-AB: An industry perspective
• The need for delivery of a new commercial model
• Objectives and structure of DRIVE-AB
• Partnership approach to delivering a new commercial model
• Beyond DRIVE-AB
David Findlay, Commercial Director of II-ID Global Franchise, GSK
4.00 Afternoon Tea
4.30 Antibiotics and their alternatives – fixing and feeding the pipeline
• Research strategy and actions
• Collaboration across countries, sectors and disciplines
• New funding instruments for SME’s
Line Matthiessen, Head of Infectious Diseases and Public
Health Unit, European Commission
5.10 Antibiotics and their alternatives - Is there a need
for innovative finance?
• EIB’s financing mechanisms supporting R&D
investments
• Overview of InnovFin Programme under Horizon 2020
Shiva Dustdar, Head of Research, Development and
Innovation Advisory, European Investment Bank (EIB)
5.50 Wellcome Trust funding opportunities
• Introducing Wellcome Trust Innovations - What is our mission?
• How we are seeking innovative therapeutics and diagnostics
to transform the treatment of infectious diseases
• Examples of success
• The selection process and a view of the investment
selection criteria
Timothy Jinks, Senior Business Analyst, Wellcome Trust Innovations
6.30 Chairman's Closing Remarks and Close of Day Two
Richard Bax, Senior Partner, TranScrip Partners
Interested in promoting your services to this market?
Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email tarri@smi-online.co.uk
Supported by
KEYNOTE
ADDRESS
KEYNOTE
ADDRESS

4. HALF-DAY PRE-CONFERENCE AM WORKSHOP
Tuesday 24th March 2015
8.30am - 12.30pm
Holiday Inn Regents Park Hotel, London, UK
A: A Vision for the Future; Designing
Antimicrobials to Meet Future Needs
Workshop Leader:
Dr Keith Williams, Director and Consultant, KW Drug
Developments Ltd & Boyd Consultants
Overview of workshop:
Strategic vision and advice, target selection and lead
optimisation, building in all requirements early. Getting
the PK/PD and dose right to take account of variability,
optimal early development and patient selection.
Global trials, databases, regulatory submissions and
interactions - insights from a Global Product Director.
Who should attend this workshop:
All those involved in drug development of antimicrobials.
The main focus is on antibacterials but the speaker has
experience of viral and fungal diseases, even vaccines,
malaria and TB. Gain insights from someone who has run
international clinical trials, Global Product teams, worked
in a CRO and as a consultant, has published and
presented widely.
Programme:
8.30 Registration and coffee
9.00 Opening remarks
9.15 Creating a target product profile
• Defining what is needed - definition of
spectrum, indications and route of
administration
10.15 Pre- clinical work to enable human studies
• What is specific to antimicrobials
10.45 Coffee break
11.15 Into man and defining the dose, PK/PD and
restrictions of use
11.45 Clinical trials, indications, geographic
considerations, databases and registration
12.15 Closing remarks
12.30 End of workshop
About Dr Keith Williams
Glaxo, AZ and Consulting - clinical trials of cefuroxime &
axetil, ceftazidime (Fortum), cefotetan, meropenem,
oxazolidinones, lipopeptides, quinolones etc. HIV
therapies, antivirals, vaccines. Honorary Fellow of Institute
of Biology, historian of the pharmaceutical industry and
clinicaltrials.StrategyteammemberandGlobalProduct
Director at ICI/AZ. Drugs from research to patent expiry.
About KW Drug Developments Ltd & Boyd Consultants:
Aim to look at strategic objects and
how they can be worked into a TPP to
give directional leads to research, how
product characters need to be built in
early. Common mistakes and strategies for efficient
development. Attendees should gain insights into the
whole development process.

5. HALF-DAY PRE-CONFERENCE PM WORKSHOP
Tuesday 24th March 2015
1.30pm - 4.30pm
Holiday Inn Regents Park Hotel, London, UK
B: Technical Aspects of Licensing
an Antibiotic
Workshop Leader:
David Scott, Consultant, PharmaConsulting
Overview of Workshop:
Learn about the key R&D-related elements involved in
the inward or outward licensing of antibiotics. The
workshop will cover an outline of the licensing process,
what technical data is needed as part of a product
licensing prospectus, what big pharma looks for and
the product evaluation and due diligence processes.
Why should you attend this workshop:
Anyone likely to be involved in the preparation of
scientific material for an outward license or in
evaluating inward licensing opportunities will benefit
from this workshop, which will cover all the key scientific
drivers and issues that need to be considered
Programme:
1.30 Registration and coffee
2.00 Introduction to licensing
• Overview of the licensing process
• Who should be included in the licencing
team
2.30 Preparing a product dossier format
• What are the key elements and issues
• What big pharma says it wants
3.00 Coffee break
3.30 Product evaluation and due diligence
• 4-step process
• Key technical issues to consider
4.15 Open discussion
4.30 End of workshop
About the workshop leader:
David Scott is a freelance healthcare consultant and a
skilled negotiator who has closed a number of major
deals for inward and outward licensing for
pharmaceutical products, delivery systems and
technologies. He has published widely (he is the author
of the best-selling report, Scrip’s Practical Guide to
Pharmaceutical Licensing”) and also provides licensing
training for a number of organizations including
C.E.L.forpharma. David has a BSc in Chemistry as well
as post-graduate qualifications in marketing and is an
accredited Certified Licensing Professional. Following
22 years working in big pharma David has spent the
past 18 years as a freelance consultant and has
provided strategic advice and successfully concluded
both inward and outward licensing agreements on
behalf of a range of worldwide clients. His client base
includes top-ranking global companies, European
regional companies, biotech companies, technology
start-ups and universities. He currently sits on the boards
of two UK-based pharmaceutical businesses.
About The European ScreeningPort:
PharmaConsulting is the
business organisation for
David Scott, a freelance
licensing and business development consultant.
www.pharmaconsulting.co.uk

6. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
SUPERBUGS AND SUPERDRUGS
Conference: Wednesday 25th & Thursday 26th March 2015, Holiday Inn Regents Park Hotel, London, UK Workshops: Tuesday 24th March 2015, London
4 WAYS TO REGISTER
www.superbugssuperdrugs.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-131
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn Regents Park Hotel, Carburton Street, London, W1W 5EE
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 28th November to receive £300 off the conference price
□ Book by 30th January to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-131 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference and 2 Workshops £2697.00 +VAT £3236.40
□ Conference and 1 Workshop £2098.00 +VAT £2517.60
□ AM □ PM
□ Conference only £1499.00 +VAT £1798.80
□ 2 Workshops £1198.00 +VAT £1437.60
□ 1 Workshop only £599.00 +VAT £718.80
□ AM □ PM
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.